Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Altamira Therapeutics Ltd (CYTO)

NASDAQ
Currency in USD
Disclaimer
2.070
-0.280(-11.91%)
Closed
After Hours
2.040-0.030(-1.449%)
Fair Value
Unlock Value
Day's Range
1.9602.490
52 wk Range
1.61052.000
Prev. Close
2.35
Open
2.41
Day's Range
1.96-2.49
52 wk Range
1.61-52
Volume
316,815
Average Volume (3m)
1,204,072
1-Year Change
-90.29%
Shares Outstanding
1,837,845
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

0.695
OPGN
-3.14%
1.000
ENVB
-1.96%
2.82
BTAI
-2.08%
0.1040
KTRA
+16.20%
2.75
STI
-5.82%
How do you feel today about CYTO?
Vote to see community's results!
or

Altamira Therapeutics Company Profile

Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.